Supernus Pharmaceuticals Inc (SUPN)
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. Co.'s products include Trokendi XR and Oxtellar XR, which are the once-daily extended release topiramate and oxcarbazepine products indicated for the treatment of epilepsy; APOKYN, which is a product indicated for the intermittent treatment of hypomobility or off episodes in patients with Parkinson's Disease (PD); XADAGO, which is an once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD; and MYOBLOC, which is a product indicated for the treatment of cervical dystonia and sialorrhea in adults.
SUPN SEC Filing Email Alerts Service
| Company Name: |
Supernus Pharmaceuticals Inc |
| Website: |
www.supernus.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding SUPN: |
54 |
| Total Market Value Held by ETFs: |
$405.15M |
| Total Market Capitalization: |
$1.66B |
| % of Market Cap. Held by ETFs: |
24.45% |
|
|
May 7, 2024 • 2:52 AM Eastern
Strong Buy (3.50 out of 4)
56th percentile
|
|
Free SUPN Email Alerts:
